Gomperts E D
Am J Hematol. 1986 Nov;23(3):295-305. doi: 10.1002/ajh.2830230315.
A considerable body of data has accumulated on the viral inactivated clotting factor concentrates. This information strongly indicates considerable safety and expected efficacy of these products. Probably most procedures are capable of inactivating large amounts of the LAV/HTLV-III virus, but there is considerable variability between products in the ability to inactivate the hepatitis viruses and perhaps also the LAV/HTLV-III. This variability is probably related to the mechanism of viral inactivation, the time of exposure to heat or chemical additives, and also the presence and type of stabilizer. So-called "second-generation" products will probably show improved elimination of more resistant viruses including the non-A, non-B forms.
关于病毒灭活凝血因子浓缩物，已经积累了大量数据。这些信息有力地表明了这些产品具有相当高的安全性和预期疗效。可能大多数生产工艺都能够灭活大量的淋巴腺病相关病毒/人嗜T淋巴细胞病毒III型（LAV/HTLV-III），但在灭活肝炎病毒以及可能还有LAV/HTLV-III的能力方面，不同产品之间存在相当大的差异。这种差异可能与病毒灭活机制、受热或化学添加剂作用的时间以及稳定剂的存在和类型有关。所谓的“第二代”产品可能在清除包括非甲、非乙型肝炎病毒在内的更具抗性的病毒方面表现出改进效果。
